（文章来源：证券日报） 证券日报网讯 12月29日，博苑股份发布公告称，博苑股份第二届董事会第十二次会议审议通过《关于 对外提供委托贷款的议案》。 ...

每经AI快讯，博苑股份（SZ 301617，收盘价：72.8元）12月29日晚间发布公告称，公司第二届第十二 次董事会会议于2025年12月28日通过"现场+通讯"的方式召开。会议审议了《关于对外提供委托贷款的 议案》。 2024年1至12月份，博苑股份的营业收入构成为：化工行业占比100.0%。 截至发稿，博苑股份市值为97亿元。 每经头条（nbdtoutiao）——绕开光刻机"卡脖子"，中国新型芯片问世！专访北大孙仲：支撑AI训练和 具身智能，可在28纳米及以上成熟工艺量产 （记者 王晓波） ...

中泰证券股份有限公司 关于山东博苑医药化学股份有限公司 对外提供委托贷款的核查意见 中泰证券股份有限公司（以下简称"中泰证券"或"保荐人"）作为山东博苑医 药化学股份有限公司（以下简称"博苑股份"、"公司"）首次公开发行股票并在创 业板上市的保荐人履行持续督导职责，根据《证券发行上市保荐业务管理办法》 《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指 引第 2 号——创业板上市公司规范运作》《深圳证券交易所创业板上市公司自律 监管指南第 1 号——业务办理》等有关规定，对博苑股份本次对外提供委托贷款 事项进行了核查，核查意见如下： 一、委托贷款事项概述 1、公司拟在确保日常经营资金需求和资金安全的前提下，利用暂时闲置的 自有资金，通过委托银行向寿光市城市建设投资开发有限公司（以下简称"寿光 城投"）提供 1.00 亿元人民币的委托贷款。委托贷款期限为自委托贷款实际发放 之日起 12 个月，用途为补充流动资金，利率为年利率 6%。寿光市城投控股集团 有限公司（以下简称"城投控股"）为寿光城投就本次委托贷款提供连带责任保 证。本次交易不属于《深圳证券交易所创业板股票上市规则》等法律法规规定的 ...

证券代码：301617 证券简称：博苑股份 公告编号：2025-057 山东博苑医药化学股份有限公司 关于对外提供委托贷款的公告 6、担保方：寿光市城投控股集团有限公司（以下简称"城投控股"） 7、履行的审议程序：本次委托贷款已经山东博苑医药化学股份有限公司（以 下简称"公司"或"博苑股份"）2025 年 12 月 28 日召开的第二届董事会第十 二次会议审议通过，无需提交股东会审议。 8、特别风险提示：公司本次委托贷款可能存在寿光城投届时不能按期、足 额偿付借款本金及利息的风险，敬请广大投资者注意投资风险。 一、委托贷款事项概述 本公司及董事会全体成员保证信息披露内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 重要内容提示： 1、委托贷款对象：寿光市城市建设投资开发有限公司（以下简称"寿光城 投"） 2、资助方式：委托贷款 3、委托贷款金额：人民币 1.00 亿元 4、委托贷款期限：12 个月 5、委托贷款利率：年利率 6.00% 1、公司拟在确保日常经营资金需求和资金安全的前提下，利用暂时闲置的 自有资金，通过委托银行向寿光城投提供 1.00 亿元人民币的委托贷款。委托贷 款期限为自委托贷款 ...

证券代码：301617 证券简称：博苑股份 公告编号：2025-056 山东博苑医药化学股份有限公司 第二届董事会第十二次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 山东博苑医药化学股份有限公司（以下简称"公司"）第二届董事会第十二次 会议通知于 2025 年 12 月 23 日以电子邮件的形式发出，2025 年 12 月 28 日于公 司会议室通过"现场+通讯"的方式召开。本次会议应出席董事 8 人，实际出席 董事 8 人（其中李成林、于国清、王恩训、袁瑞、高磊、张志红、吕志果通过通 讯方式参加会议）。会议由董事长李成林先生召集并主持，公司高级管理人员列 席了会议。会议的通知及召开程序符合相关法律法规和《公司章程》的规定，会 议合法、有效。全体董事审议并通过了如下议案： 二、董事会会议审议情况 1、审议通过《关于对外提供委托贷款的议案》 公司拟在确保日常经营资金需求和资金安全的前提下，利用暂时闲置的自有 资金，通过委托银行向寿光市城市建设投资开发有限公司（以下简称"寿光城投"） 提供 1.00 亿元人民币的委托贷款。 ...

Core Viewpoint - The company, Boyuan Co., Ltd. (301617), is positioned as a leader in the fine chemical sector, successfully navigating the transition from "scale expansion" to "green high-quality development" in the context of the global "dual carbon" strategy [1] Group 1: Circular Economy and Business Model - Boyuan Co., Ltd. has established a circular economy business model centered on the recovery and utilization of iodine and precious metals, differentiating itself from traditional chemical enterprises [2] - This model allows the company to procure iodine and precious metal-containing waste from upstream enterprises, effectively addressing waste disposal challenges while reducing raw material dependency and production costs [2] - The circular economy approach not only mitigates risks associated with imported raw material price fluctuations but also enhances customer trust, leading to long-term cooperation agreements [2] Group 2: Integrated Service Capability - The company has developed a comprehensive service capability that spans from basic chemical raw material supply to hazardous waste resource utilization and product processing, fostering mutually beneficial strategic partnerships with major clients [3] - Boyuan Co., Ltd.'s iodine resource utilization business is recognized for its advanced recycling processes and large-scale processing capabilities, placing it in a leading position within the industry [3] Group 3: Technological Innovation and Product Development - The company emphasizes technological innovation as a key driver of growth, increasing R&D investment and accelerating the commercialization of research outcomes [5] - Boyuan Co., Ltd. is focusing on high-end and emerging fields such as new materials and new energy, aiming to enhance product structure and extend the industrial chain [5] - The company actively participates in the establishment of industry standards, having contributed to the formulation of 3 industry standards and 11 group standards, thereby enhancing its professional influence [4] Group 4: Strategic Growth and Market Positioning - Boyuan Co., Ltd. maintains a cautious yet open approach to mergers and acquisitions, considering opportunities that align with its strategic goals to enhance core competitiveness [6] - The company has outlined a clear roadmap for high-quality development during the 14th Five-Year Plan period, focusing on talent, R&D, market expansion, governance, and green development [6] - The company is committed to integrating into local industrial layouts and development plans, promoting sustainable practices through increased environmental investment and resource recycling [7]

Core Viewpoint - The company is actively researching and developing products related to the application of iodides in the perovskite field, with ongoing projects but no products available for sale yet [1]. Group 1 - The company has acknowledged the potential of iodides in the perovskite sector [1]. - Technical research and product development efforts are currently underway [1]. - The related R&D projects are in progress but have not yet resulted in product sales [1].

Group 1 - The company is exploring the application of iodides in the perovskite field and has initiated technical research and product development in this area [2] - Current research and development projects related to iodides and perovskites are in progress, but no products have been commercialized yet [2]

Group 1 - The core business of Shandong Boyuan Pharmaceutical Chemical Co., Ltd. includes the research, production, and sales of fine chemicals, with a focus on organic iodides (74.56% of revenue), specialty functional chemicals (12.79%), trading (9.94%), and others (2.72%) [2] - As of December 10, 2025, the company reported a revenue of 1.073 billion yuan, representing a year-on-year growth of 6.60%, while the net profit attributable to shareholders decreased by 22.53% to 132 million yuan [2] - The company has distributed a total of 88.408 million yuan in dividends since its A-share listing [3] Group 2 - On December 19, 2025, Boyuan shares increased by 0.53%, with a trading volume of 93.8648 million yuan, and a net financing purchase of 448,700 yuan [1] - The total margin trading balance for Boyuan shares reached 142 million yuan, accounting for 3.68% of the circulating market value, which is above the 70th percentile of the past year [1] - As of December 19, 2025, there were no shares sold or repaid in the securities lending market, indicating a high level of demand for borrowing [1]

Group 1 - The core viewpoint of the news is that Shandong Boyuan Pharmaceutical Chemical Co., Ltd. has shown fluctuations in its stock performance and financing activities, indicating potential investor interest and market dynamics [1][2]. Group 2 - On December 18, Boyuan shares fell by 2.24%, with a trading volume of 66.31 million yuan. The financing buy-in amount was 5.13 million yuan, while the financing repayment was 3.34 million yuan, resulting in a net financing buy-in of 1.79 million yuan. The total financing and securities balance reached 142 million yuan [1]. - As of December 18, the financing balance of Boyuan shares was 142 million yuan, accounting for 3.69% of the circulating market value [1]. - In terms of securities lending, there were no shares repaid or sold on December 18, with a remaining balance of 0 shares and 0 yuan [1]. Group 3 - Boyuan, established on August 6, 2008, is located in Shouguang City, Shandong Province, and specializes in the research, production, and sales of fine chemicals, including organic and inorganic iodides, precious metal catalysts, and luminescent materials. The main business revenue composition includes iodides (74.56%), specialty functional chemicals (12.79%), trading business (9.94%), and others (2.72%) [2]. - For the period from January to September 2025, Boyuan achieved an operating income of 1.073 billion yuan, representing a year-on-year growth of 6.60%. However, the net profit attributable to the parent company was 132 million yuan, a decrease of 22.53% year-on-year [2]. Group 4 - Since its A-share listing, Boyuan has distributed a total of 88.41 million yuan in dividends [3]. - As of September 30, 2025, the top ten circulating shareholders of Boyuan include several new institutional investors, with notable holdings from Zhonghang New Start Flexible Allocation Mixed A (holding 1.3456 million shares) and Hong Kong Central Clearing Limited (holding 964,400 shares) [3].